U.S. Physician Perspectives on International HTA and Drug Value Assessment

Magnolia Market Access surveyed 100 U.S. physicians treating asthma, COPD, and diabetes to understand differences in the perceived value of innovative medicines as compared to benefit ratings assigned by Germany’s G-BA, the health technology assessment body responsible for evaluating new pharmaceutical treatments and health technologies.

This infographic shows U.S. physician perspectives on direct clinical benefits of innovative medicines and key indirect benefits that matter most to patients and caregivers.